Novartis breast cancer med Kisqali, struggling against Ibrance, finds niche in younger women

9th November 2017 Uncategorised 0

Novartis breast cancer med Kisqali has struggled to gain traction in a field dominated by Pfizer blockbuster Ibrance. So it’s going where Ibrance hasn’t.

More: Novartis breast cancer med Kisqali, struggling against Ibrance, finds niche in younger women
Source: fierce